The application of the first gene therapy approach for spinal muscular atrophy (SMA) linked with variants in survival motor neuron 1 (SMN1) provides potential strategies for intervention for SMARD1. This evidence concerns the gene IGHMBP2 and proximal spinal muscular atrophy.